vTv Therapeutics (VTVT) Revenue & Revenue Breakdown
vTv Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.02M
Main Segment (Y)
Reportable Segment
vTv Therapeutics Revenue by Period
vTv Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $1.02M | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $2.02M | -49.61% |
| 2021-12-31 | $4.00M | -37.56% |
| 2020-12-31 | $6.41M | 132.05% |
| 2019-12-31 | $2.76M | -77.77% |
| 2018-12-31 | $12.43M | 4172.85% |
| 2017-12-31 | $291.00K | -54.10% |
| 2016-12-31 | $634.00K | 22.16% |
| 2015-12-31 | $519.00K | -66.49% |
| 2014-12-31 | $1.55M | 58.71% |
| 2013-12-31 | $976.00K | - |
vTv Therapeutics generated $1.02M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 36.79% compared to the same period a year ago.
vTv Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $17.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $1.00M | -11211.11% |
| 2023-12-31 | $-9.00K | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $9.00K | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $9.00K | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $9.00K | -99.55% |
| 2022-03-31 | $2.00M | 22122.22% |
| 2021-12-31 | $9.00K | -99.70% |
| 2021-09-30 | $3.00M | 33233.33% |
| 2021-06-30 | $9.00K | -99.09% |
| 2021-03-31 | $987.00K | -84.58% |
| 2020-12-31 | $6.40M | 91314.29% |
| 2020-09-30 | $7.00K | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $8.00K | 14.29% |
| 2019-12-31 | $7.00K | -12.50% |
| 2019-09-30 | $8.00K | -99.56% |
| 2019-06-30 | $1.83M | 98.48% |
| 2019-03-31 | $921.00K | -79.63% |
| 2018-12-31 | $4.52M | 33.99% |
| 2018-09-30 | $3.38M | 36.47% |
| 2018-06-30 | $2.47M | 19.82% |
| 2018-03-31 | $2.06M | 785.84% |
| 2017-12-31 | $233.00K | 1453.33% |
| 2017-09-30 | $15.00K | 15.38% |
| 2017-06-30 | $13.00K | -56.67% |
| 2017-03-31 | $30.00K | -21.05% |
| 2016-12-31 | $38.00K | - |
| 2016-09-30 | $38.00K | -79.12% |
| 2016-06-30 | $182.00K | -51.60% |
| 2016-03-31 | $376.00K | 66.37% |
| 2015-12-31 | $226.00K | 69.92% |
| 2015-09-30 | $133.00K | 20.91% |
| 2015-06-30 | $110.00K | 120.00% |
| 2015-03-31 | $50.00K | -94.65% |
| 2014-12-31 | $934.00K | 133.50% |
| 2014-09-30 | $400.00K | 99.00% |
| 2014-06-30 | $201.00K | 1335.71% |
| 2014-03-31 | $14.00K | - |
vTv Therapeutics generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
vTv Therapeutics Revenue Breakdown
vTv Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| Reportable Segment | $1.00M |
Latest
vTv Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).
vTv Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FBIO | Fortress Biotech | $55.13M | $13.14M |
| CUE | Cue Biopharma | $5.49M | $2.95M |
| VTVT | vTv Therapeutics | $1.02M | - |
| MNOV | MediciNova | $1.00M | - |
| COEP | Coeptis Therapeutics | - | $62.87K |
| ESLA | Estrella Immunopharma | - | - |
| JUNS | Jupiter Neurosciences | - | - |
| ALGS | Aligos Therapeutics | - | $311.00K |
| GNTA | Genenta Science S.p.A. | - | - |
| TELO | Telomir Pharmaceuticals | - | - |
| ACRV | Acrivon Therapeutics | - | - |